DOSIMETRIC MEASUREMENTS USING 124-I-PET DURING 131-I THERAPY OF HYPERTHYROIDISM

DOSIMETRIC MEASUREMENTS USING 124-I-PET DURING 131-I THERAPY OF HYPERTHYROIDISM
124-I measurements has been performed in 12 patients with toxic multinodular goiter, 2 with toxic adenoma, and 1 with Graves disease. 131-I therapeutic dosis and 30<196>40 MBq 124-I were administere orally, simultaneously. PET images (10 minutes transmission and 75000 coincidental events in emission phase) were acquired using a whole-body PET-scanner (GE Advance). In each patient, 4<196>5 scans were performed in two weeks, starting 24 hours after application. In all patients scintillation probe measurements of 131-I kinetics were performe simultaneously. Uptake values and effective half-lives of 131-I adn 124-I showed mean deviations of 1.8% and 4 hours, respectively. Correlation coefficient was: 0.99 for uptake and 0.88 for effective half-life. Additional evaluation of regional functionally autonomous and paranodular tissue revealed considerable diference both in 124-I specific uptake (nodules: 12.6<196>29.3 KBq/ml/MBq, rest thyroid tissue: 2.0<196>8.3 KBq/ml/MBq) and in efective half-lives (nodules: 93<196>193 hours, rest thyroid tissue 107<196>162 hours) which concerned different nodules within the same thyroid, as well. Results indicate that 124-I PET enables a precise measurement of the regional radioiodine distribution and kinetics in functionally active thyroid tissue, necessary for the accurate calculation of the target dose to be delivered by radioiodine therapy.

Attachment	Size
Glasnik 6 E 1.pdf	15.53 KB